FMR LLC boosted its position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 797.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,299,929 shares of the company's stock after purchasing an additional 5,598,190 shares during the period. FMR LLC owned about 2.63% of BioNTech worth $748,243,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. GAMMA Investing LLC raised its holdings in shares of BioNTech by 86.9% in the second quarter. GAMMA Investing LLC now owns 512 shares of the company's stock valued at $41,000 after purchasing an additional 238 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company's stock valued at $43,000 after buying an additional 252 shares during the last quarter. Planning Capital Management Corp lifted its position in BioNTech by 45,000.0% during the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company's stock worth $54,000 after buying an additional 450 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company's stock worth $55,000 after buying an additional 388 shares during the last quarter. Finally, Daiwa Securities Group Inc. grew its holdings in shares of BioNTech by 430.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company's stock valued at $155,000 after acquiring an additional 1,562 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.
BioNTech Stock Performance
NASDAQ BNTX traded down $2.33 on Friday, reaching $118.39. The stock had a trading volume of 518,891 shares, compared to its average volume of 815,873. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The company has a market cap of $28.38 billion, a P/E ratio of -56.94 and a beta of 0.26. The firm has a fifty day moving average of $113.69 and a two-hundred day moving average of $98.50.
BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $514.08 million. During the same period in the previous year, the company posted $0.73 earnings per share. The firm's revenue for the quarter was up 38.9% compared to the same quarter last year. On average, equities research analysts anticipate that BioNTech SE will post -3.68 EPS for the current year.
Wall Street Analysts Forecast Growth
BNTX has been the subject of several recent research reports. Evercore ISI raised BioNTech from an "in-line" rating to an "outperform" rating and increased their price target for the company from $110.00 to $125.00 in a research report on Tuesday, November 19th. HC Wainwright reissued a "buy" rating and issued a $150.00 target price on shares of BioNTech in a research note on Monday, November 18th. Jefferies Financial Group raised shares of BioNTech from a "hold" rating to a "buy" rating and upped their price target for the stock from $96.00 to $150.00 in a research report on Tuesday, September 17th. UBS Group lifted their price objective on shares of BioNTech from $97.00 to $131.00 and gave the company a "neutral" rating in a research report on Wednesday, September 18th. Finally, Canaccord Genuity Group upped their target price on shares of BioNTech from $171.00 to $171.44 and gave the company a "buy" rating in a report on Wednesday. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $138.67.
Get Our Latest Report on BioNTech
About BioNTech
(
Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Further Reading
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
